Halozyme Therapeutics (HALO) Debt Ratio (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Debt Ratio data on file, last reported at 0.8 in Q1 2026.

• Debt Ratio for Q1 2026 came in at 0.8, up 16.92% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.8 (up 16.92% YoY), and the FY2025 annual result was 0.85, up 16.27% from the prior year.
• Debt Ratio retreated to 0.8 in Q1 2026 per HALO's latest filing, from 0.85 in the prior quarter.
• Over five years, Debt Ratio peaked at 0.88 in Q1 2023 and troughed at 0.06 in Q2 2022.
• A 5-year average of 0.7 and a median of 0.79 in 2023 frame the typical range for Debt Ratio.
• The sharpest annual moves came in 2022 and 2023: Debt Ratio slumped 36.03% in 2022, then jumped 1386.14% in 2023.
• A 5-year view of Debt Ratio shows it stood at 0.82 in 2022, then gained by 5.76% to 0.86 in 2023, then retreated by 15.64% to 0.73 in 2024, then increased by 16.27% to 0.85 in 2025, then fell by 5.43% to 0.8 in 2026.
• Business Quant data shows HALO's Debt Ratio at 0.8 in Q1 2026, 0.85 in Q4 2025, and 0.68 in Q3 2025.